Elizabeth Z Zakka
Abstract: Novel Coronavirus Disease (COVID-19) is caused by a zoonotic virus that belongs to the coronavirus family with a close relationship with the bat-SARS-like coronavirus strain BatCov RaTG13. Up until this day, no treatment option has been found to be completely effective against this virus clinically and theoretically. Veclury (remdesivir) is an RNA polymerase antiviral made by Gilead Sciences, Inc. and it has shown some promising results for patients hospitalized due to COVID-19 with mild/moderate and severe disease. According to this, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for healthcare providers permitting the emergency use of remdesivir for the treatment of COVID-19 hospitalized patients. The FDA based its EUA on data collected from clinical trials that used remdesivir. Examples of these trials are National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT-1) Trial in Subjects with Mild/Moderate and Severe Covid-19, Study GS-US-540-5773; Remdesivir for 5 or 10 Days in Patients with Severe Covid-19; a randomized, open label, multi-center clinical trial, and Study GS-US-540-5774; Effect of Remdesivir vs. Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19, A Randomized Clinical Trial. According to these trials, and others as well, remdesivir could be used as an intravenous infusion for 5 to 10 days depending on the severity of the disease.
Keywords: COVID-19, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, Remdesivir, Veclury